Physician profile
Maher B Awad
NPI 1134106677
$9,244.24
in general payments reported to CMS, 2019-2025
16 companies · $1,207 in 2025
The $1,207 reported for 2025 was more than what 84% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,117 · 2020: $968 · 2021: $1,413 · 2022: $1,185 · 2023: $1,830 · 2024: $1,524 · 2025: $1,207.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,561.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,561.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,669.06 | 2021-2025 | Vraylar |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,008.85 | 2020-2025 | Caplyta |
| Sunovion Pharmaceuticals INC. | $909.41 | 2019-2021 | |
| Allergan, INC. | $559.20 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $498.72 | 2019-2024 | Invega Sustenna |
| Alkermes, INC. | $462.96 | 2019-2024 | Aristada, Lybalvi |
| Otsuka America Pharmaceutical, INC. | $358.79 | 2021-2024 | Abilify Maintena, Rexulti, Abilify Asimtufii |
| Teva Pharmaceuticals USA, INC. | $311.44 | 2021-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Genzyme Corporation | $123.33 | 2019 | |
| Avanir Pharmaceuticals, INC. | $106.67 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $91.91 | 2021-2022 | |
| Lundbeck LLC | $55.54 | 2019-2025 | Rexulti |
| Indivior INC. | $49.51 | 2019-2023 | Perseris |
| Shire North American Group INC | $14.44 | 2019 | |
| Axsome Therapeutics, INC. | $13.20 | 2024 | Auvelity |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $11.21 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maher Awad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.